Marine Natural Products: A Source of Novel Anticancer Drugs. 2019

Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
Clinical Research Centre, Karolinska University Hospital, Novum, 14157 Huddinge, Stockholm, Sweden.

Cancer remains one of the most lethal diseases worldwide. There is an urgent need for new drugs with novel modes of action and thus considerable research has been conducted for new anticancer drugs from natural sources, especially plants, microbes and marine organisms. Marine populations represent reservoirs of novel bioactive metabolites with diverse groups of chemical structures. This review highlights the impact of marine organisms, with particular emphasis on marine plants, algae, bacteria, actinomycetes, fungi, sponges and soft corals. Anti-cancer effects of marine natural products in in vitro and in vivo studies were first introduced; their activity in the prevention of tumor formation and the related compound-induced apoptosis and cytotoxicities were tackled. The possible molecular mechanisms behind the biological effects are also presented. The review highlights the diversity of marine organisms, novel chemical structures, and chemical property space. Finally, therapeutic strategies and the present use of marine-derived components, its future direction and limitations are discussed.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001688 Biological Products Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay. Biologic,Biologic Drug,Biologic Product,Biological,Biological Drug,Biological Medicine,Biological Product,Biologics,Biopharmaceutical,Natural Product,Natural Products,Biologic Drugs,Biologic Medicines,Biologic Pharmaceuticals,Biologic Products,Biological Drugs,Biological Medicines,Biologicals,Biopharmaceuticals,Products, Biological,Drug, Biologic,Drug, Biological,Drugs, Biologic,Drugs, Biological,Medicine, Biological,Medicines, Biologic,Medicines, Biological,Pharmaceuticals, Biologic,Product, Biologic,Product, Biological,Product, Natural
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D059001 Aquatic Organisms Organisms that live in water. Marine Organisms,Aquatic Organism,Marine Organism,Organism, Aquatic,Organism, Marine,Organisms, Aquatic,Organisms, Marine

Related Publications

Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
February 2005, Molecular cancer therapeutics,
Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
December 2022, Cancers,
Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
August 2023, Current medicinal chemistry,
Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
June 1993, Current opinion in biotechnology,
Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
October 2023, Current medicinal chemistry,
Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
June 2021, Journal of medicinal chemistry,
Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
August 2021, Marine drugs,
Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
December 2022, European journal of medicinal chemistry,
Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
April 2019, Expert opinion on therapeutic patents,
Shaden A M Khalifa, and Nizar Elias, and Mohamed A Farag, and Lei Chen, and Aamer Saeed, and Mohamed-Elamir F Hegazy, and Moustafa S Moustafa, and Aida Abd El-Wahed, and Saleh M Al-Mousawi, and Syed G Musharraf, and Fang-Rong Chang, and Arihiro Iwasaki, and Kiyotake Suenaga, and Muaaz Alajlani, and Ulf Göransson, and Hesham R El-Seedi
January 2017, PloS one,
Copied contents to your clipboard!